Payment overview · 2025
General Payments
$1,059.49
56 reported records · 15 companies
Healthcare provider profile · identity verified
Haley Beecham Phillips, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAWRENCEBURG, TN · NPI 1104308006
Verified facts
What the public records show
CMS Open Payments records show Haley Beecham Phillips, FNP-C received $1,059.49 in general payments during 2025 across 56 reported records.
Novo Nordisk Inc accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $245.43 | 23.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.60 | 19.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.31 | 16.7% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $98.14 | 9.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.93 | 6.9% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.21 | 5.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.90 | 3.7% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $32.10 | 3.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.63 | 3.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.06 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.94 | 1.7% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $16.46 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.37 | 1.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.19 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.22 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,059.49 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $169.21 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.58 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $126.58 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.79 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.93 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $98.14 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.22 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.93 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $72.93 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $55.21 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.09 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $32.10 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.11 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 512 | 140 |
| Lisinopril | Lisinopril | 447 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 106 |
| Omeprazole | Omeprazole | 399 | 111 |
| Losartan Potassium | Losartan Potassium | 362 | 109 |
| Furosemide | Furosemide | 359 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 81 |
| Metformin Hcl | Metformin Hcl | 256 | 77 |
| Alprazolam | Alprazolam | 243 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 219 | 59 |
| Eliquis | Apixaban | 209 | 47 |
| Gabapentin | Gabapentin | 201 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 60 |
| Trazodone Hcl | Trazodone Hcl | 186 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 50 |
| Potassium Chloride | Potassium Chloride | 176 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 50 |
| Sertraline Hcl | Sertraline Hcl | 150 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 32 |
| Carvedilol | Carvedilol | 130 | 31 |
| Montelukast Sodium | Montelukast Sodium | 129 | 29 |
| Alendronate Sodium | Alendronate Sodium | 119 | 30 |
| Allopurinol | Allopurinol | 117 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 28 |
| Ozempic | Semaglutide | 110 | 23 |
| Buspirone Hcl | Buspirone Hcl | 109 | 29 |
| Benazepril Hcl | Benazepril Hcl | 106 | 27 |
| Ezetimibe | Ezetimibe | 101 | 35 |
| Warfarin Sodium | Warfarin Sodium | 101 | 18 |
| Simvastatin | Simvastatin | 97 | 29 |
| Glipizide Er | Glipizide | 87 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 15 |
| Atenolol | Atenolol | 79 | 26 |
| Azithromycin | Azithromycin | 79 | 73 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 21 |
| Spironolactone | Spironolactone | 74 | 23 |
| Xarelto | Rivaroxaban | 73 | 21 |
| Metformin Hcl Er | Metformin Hcl | 71 | 21 |
| Glipizide | Glipizide | 69 | 20 |
| Nifedipine Er | Nifedipine | 67 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 24 |
| Fluconazole | Fluconazole | 62 | 44 |
| Meloxicam | Meloxicam | 60 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 20 |
| Prednisone | Prednisone | 59 | 52 |
| Diazepam | Diazepam | 58 | 12 |
| Meclizine Hcl | Meclizine Hcl | 58 | 26 |
| Bupropion Xl | Bupropion Hcl | 57 | 13 |
| Chlorthalidone | Chlorthalidone | 56 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 16 |
| Farxiga | Dapagliflozin Propanediol | 54 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 41 |
| Famotidine | Famotidine | 51 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 15 |
| Jardiance | Empagliflozin | 48 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 13 |
| Mounjaro | Tirzepatide | 47 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 18 |
| Nystatin | Nystatin | 46 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 12 |
| Lovastatin | Lovastatin | 45 | 13 |
| Valsartan | Valsartan | 45 | suppressed |
| Irbesartan | Irbesartan | 44 | suppressed |
| Mirtazapine | Mirtazapine | 43 | 14 |
| Pregabalin | Pregabalin | 42 | 14 |
| Propranolol Hcl | Propranolol Hcl | 42 | 13 |
| Finasteride | Finasteride | 40 | 11 |
| Ibuprofen | Ibuprofen | 40 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 28 |
| Ramipril | Ramipril | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Indapamide | Indapamide | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Linzess | Linaclotide | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,059.49 · 56 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, CONTRAVE, Cologuard Collection Kit, ECC Solutions, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, NEXLETOL, NURTEC ODT, Ozempic, Paradise Ultrasound Renal Denervation System, QULIPTA, REPATHA, Rybelsus, UBRELVY, VIBERZI, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error